FAQs FOR MOG(35-55)
MOG (35-55)
MOG (35-55) is a synthetic 21-amino-acid peptide fragment derived from myelin oligodendrocyte glycoprotein (MOG). It is widely used in experimental immunology and neuroscience research, particularly for inducing experimental autoimmune encephalomyelitis (EAE) in susceptible laboratory animals.
EAE is one of the most established experimental models for investigating autoimmune demyelination, neuroinflammation, T-cell-mediated immune responses, and central nervous system (CNS) injury. Because MOG is associated with the myelin sheath surrounding neurons, immune responses directed against MOG-derived peptides can be used to investigate mechanisms involved in inflammatory demyelinating disease.
MOG (35-55) should therefore be understood primarily as a research antigen and experimental model reagent, rather than as a peptide intended to treat multiple sclerosis or other neurological disorders.
What Is MOG?
Myelin oligodendrocyte glycoprotein (MOG) is a relatively minor component of the CNS myelin membrane. It is expressed on the outer surface of oligodendrocytes and myelin sheaths, making it accessible to components of the immune system.
The MOG protein has attracted considerable interest in neuroimmunology because immune recognition of MOG can participate in experimental models of CNS inflammation.
The MOG (35-55) peptide represents a specific region of the larger MOG protein and can function as an antigenic peptide in experimental immune models.
Basic Characteristics
- Name: Myelin Oligodendrocyte Glycoprotein (35-55)
- Abbreviation: MOG (35-55)
- Length: 21 amino acids
- Type: Synthetic peptide antigen
- Parent protein: Myelin oligodendrocyte glycoprotein
- Primary research application: Experimental autoimmune encephalomyelitis
- Research fields: Neuroimmunology, autoimmune disease, CNS inflammation, demyelination
- Common experimental species: Mouse and rat models
MOG (35-55) and Experimental Autoimmune Encephalomyelitis
The most important application of MOG (35-55) is its use in experimental models of EAE.
EAE is an established animal model used to investigate inflammatory demyelinating diseases of the central nervous system. Depending on the animal strain, peptide sequence, experimental design, and immune-adjuvant conditions, administration of an encephalitogenic MOG peptide can produce an autoimmune response directed toward CNS myelin.
This can lead to neurological inflammation and demyelination that researchers can monitor over time.
The model allows investigators to study mechanisms that would be difficult or impossible to examine directly in living human CNS tissue.
How MOG (35-55) Works as a Research Antigen
MOG (35-55) functions primarily by providing an antigenic target for adaptive immune responses.
In susceptible experimental animals, immune cells can recognize the peptide through antigen-presentation pathways. This can result in activation and expansion of antigen-specific T-cell populations.
Antigen Presentation
Following exposure to the peptide, antigen-presenting cells can process and present relevant peptide sequences to T lymphocytes.
Depending on the experimental system, presentation through major histocompatibility complex (MHC) molecules can activate antigen-specific T cells.
This antigen-specific immune activation is a central component of MOG-induced EAE research.
T-Cell Activation
MOG (35-55) has been extensively studied for its ability to generate myelin-reactive T-cell responses.
Activated T cells can migrate toward the CNS and participate in inflammatory processes involving the brain and spinal cord.
Researchers can subsequently investigate the cellular and molecular events associated with CNS inflammation and demyelination.
Neuroinflammation
The immune response generated in EAE can involve multiple immune-cell populations and inflammatory mediators.
Research may examine:
- T lymphocytes
- B lymphocytes
- Macrophages
- Microglia
- Dendritic cells
- Cytokines
- Chemokines
- Blood-brain barrier alterations
- Inflammatory signaling pathways
This makes the MOG (35-55) model useful for studying interactions between the peripheral immune system and the CNS.
MOG (35-55) and Demyelination
Myelin is a specialized insulating structure surrounding many neuronal axons.
Inflammatory damage to myelin can interfere with normal nerve conduction and produce neurological abnormalities.
In MOG-induced EAE, immune-mediated inflammation can result in demyelinating lesions within the CNS. Researchers can use these lesions to investigate mechanisms of myelin injury, immune-cell infiltration, and subsequent tissue responses.
Histological and molecular analyses can provide information about:
- Myelin integrity
- Axonal damage
- Immune-cell infiltration
- Microglial activation
- Astrocyte responses
- Inflammatory cytokine expression
- Remyelination processes
MOG (35-55) and Multiple Sclerosis Research
EAE is commonly described as a model of multiple sclerosis (MS), but it is important to recognize that EAE is not identical to human MS.
Human multiple sclerosis is a complex disease involving genetic, environmental, immunological, and neurological factors. Different EAE models reproduce only selected aspects of human disease.
MOG (35-55) therefore serves as a tool for investigating specific biological mechanisms relevant to autoimmune demyelination rather than providing a complete reproduction of MS.
MOG (35-55) and Optic Neuritis Research
MOG-related experimental models can also be used to study optic nerve inflammation and injury.
Optic neuritis involves inflammatory damage affecting the optic nerve and can produce visual abnormalities.
Researchers can use experimental demyelination models to investigate:
- Optic nerve inflammation
- Immune-cell infiltration
- Myelin loss
- Axonal injury
- Neurodegeneration
- Glial responses
- Potential neuroprotective mechanisms
This makes MOG-based models relevant to experimental neuro-ophthalmology.
MOG (35-55) and Immune-Cell Research
MOG (35-55) is frequently used to investigate the behavior of antigen-specific immune cells.
Researchers can examine how different immune populations contribute to disease initiation, progression, and resolution.
Important research areas include:
T-Cell Biology
Studies can investigate antigen-specific T-cell activation, differentiation, migration, and cytokine production.
Regulatory T Cells
Researchers can evaluate mechanisms through which regulatory T cells suppress or modify autoimmune responses.
B-Cell Responses
Although T-cell-mediated mechanisms are central to many EAE models, B cells and antibody responses can also contribute to CNS autoimmunity.
Microglia and Macrophages
These cells are important mediators of neuroinflammation and can participate in myelin damage and subsequent tissue remodeling.
MOG (35-55) and Cytokine Research
MOG-induced EAE provides a useful experimental system for studying inflammatory cytokine networks.
Depending on the model and disease phase, investigators may examine pathways involving cytokines such as:
- Interferon-γ
- Interleukin-17
- Tumor necrosis factor
- Interleukin-6
- Interleukin-1
- Regulatory cytokines
These signaling systems can help researchers understand how adaptive immune responses contribute to CNS inflammation.
Species and Sequence Variants
An important consideration when working with MOG (35-55) is that the peptide sequence can differ between species.
Mouse/rat and human MOG-derived peptides are not necessarily identical. Consequently, the biological activity and experimental suitability of one sequence cannot automatically be assumed to apply to another species.
Research documentation should therefore clearly identify:
- Species of origin
- Exact amino-acid sequence
- Peptide length
- Terminal modifications, if any
- Purity
- Experimental application
Common Mouse/Rat MOG (35-55) Sequence
A commonly used mouse/rat MOG (35-55) sequence is:
MEVGWYRSPFSRVVHLYRNGK
Human MOG-derived sequences can differ and should be specified separately rather than treated as interchangeable with the mouse/rat peptide.
Research Applications
MOG (35-55) is used in a broad range of experimental applications.
Experimental Autoimmune Encephalomyelitis
The peptide is widely used to establish EAE models for investigating CNS autoimmunity and inflammatory demyelination.
Autoimmune Disease Research
Researchers can investigate mechanisms underlying antigen-specific autoimmune responses.
Neuroinflammation
MOG-based models allow researchers to study inflammatory signaling within the brain, spinal cord, and optic nervous system.
Demyelination and Remyelination
The model can be used to investigate how myelin is damaged and how nervous tissue responds to inflammatory injury.
Drug Discovery
Experimental MOG-induced EAE models are frequently used to evaluate potential therapeutic strategies targeting immune or inflammatory pathways.
Immunology
MOG (35-55) provides a defined antigen for studying antigen-specific T-cell responses and immune tolerance.
Neuroprotection
Researchers can examine whether experimental interventions protect neurons, axons, oligodendrocytes, or myelin during inflammatory CNS injury.
Why MOG (35-55) Is Important in Research
One of the advantages of MOG (35-55) is that it provides researchers with a defined molecular antigen rather than relying on an undefined mixture of myelin proteins.
This allows experimental systems to be designed around a known peptide sequence and provides greater control over investigations of antigen-specific immunity.
Researchers can consequently examine how specific immune responses contribute to CNS pathology and how experimental interventions modify these responses.
Medical and Regulatory Status
MOG (35-55) is not an FDA-approved therapeutic drug and should not be represented as a treatment for multiple sclerosis, optic neuritis, autoimmune disease, or other human medical conditions.
Its principal role is as a research reagent and experimental antigen used in laboratory and animal studies.
Importantly, results obtained from MOG-induced EAE should not automatically be interpreted as evidence that the MOG (35-55) peptide itself has therapeutic effects in humans.
Safety and Research Considerations
MOG (35-55) is biologically active in susceptible experimental systems because its purpose is to generate an antigen-specific immune response.
Consequently, it should be handled as a research reagent according to appropriate institutional laboratory procedures.
Its biological effects depend heavily on:
- Species
- Animal strain
- Peptide sequence
- Experimental formulation
- Antigen-presentation environment
- Experimental protocol
- Immune status
- Genetic background
The same peptide can therefore produce substantially different outcomes in different experimental models.
Quality-Control Considerations
Research-grade MOG (35-55) should be appropriately characterized before use in controlled experiments.
Relevant quality-control parameters may include:
- Peptide identity
- HPLC purity
- Mass spectrometry
- Peptide content
- Exact amino-acid sequence
- Water content
- Residual-solvent analysis where applicable
- Endotoxin testing where required
- Sterility or microbiological testing where appropriate
- Storage and stability evaluation
For immunological experiments, consistent peptide quality is particularly important because impurities or degradation products can influence experimental immune responses.
Summary
MOG (35-55) is a synthetic 21-amino-acid peptide derived from myelin oligodendrocyte glycoprotein and is primarily used as an experimental antigen in neuroimmunology research.
Its best-known application is the induction of experimental autoimmune encephalomyelitis (EAE) in susceptible laboratory animals. This model allows researchers to investigate antigen-specific T-cell responses, neuroinflammation, demyelination, immune-cell infiltration, blood-brain barrier changes, and CNS tissue injury.
MOG (35-55) has also become an important research tool for studying multiple-sclerosis-related mechanisms, optic neuritis, autoimmune neuroinflammation, myelin biology, remyelination, neuroprotection, and experimental drug development.
Because MOG sequences vary between species, researchers should carefully distinguish mouse/rat and human-derived peptide variants. Most importantly, MOG (35-55) should be understood as a laboratory research antigen rather than a therapeutic peptide, and findings from animal EAE models cannot be directly equated with clinical efficacy in humans.